TP53 and neoplasm: Barris et al. [31] performed a targeted Next-Generation Sequencing (NGS) analysis to detect mutated alterations in TP53, RB1, ATRX, DLG2, PTEN, MET, and SLC19A1 genes in primary tumor samples as well as in ctDNA collected from blood samples of 7 OS patients at various time points (4 weeks prior-treatment of primary tumor-134 weeks post-treatment).